16/04/2026 – AB Science provides an update on its clinical development program Download PDF Category: 2026By Alexis BERNARD16 April 2026 Partager cet article Share on LinkedInShare on LinkedIn Share on XShare on X Share on FacebookShare on Facebook Share on WhatsAppShare on WhatsApp Author: Alexis BERNARD Post navigationPreviousPrevious post:AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALSNextNext post:New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patientsRelated PostsAB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs10 July 2026AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development8 July 2026AB Science announces the successful completion of a EUR 2.3 million private placement1 July 2026
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026
AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs10 July 2026
AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development8 July 2026
